Company Overview and News

0
Watchdog Mauls Brexiteers' Dream - Bloomberg

2018-06-18 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
NRDEF NRBAY AMUN

0
The View From Amundi: Absolute Return And Factor Models

2018-06-12 seekingalpha
On May 30, CAIA France sponsored a panel discussion on absolute return strategies, held at the headquarters of Amundi Asset Management, on the Boulevard Pasteur in Paris.
AMUN

9
Credit Agricole caught in fixed-income slump

2018-05-16 thestar.com.my
Downtrend: The sign of French bank Credit Agricole in Lille, northern France. The bank’s trading revenue slumped in the first three months of the year. — AFP
BNPZY SCGLF BNPQY ACA SCGLY RF GLE BNPQF CRARY CRARF AMUN

0
Chaos-Fleeing Investors See Europe's Populist East as No Russia - Bloomberg

2018-04-16 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
AMUN

13
Kremlin-Cozy Firms Go From Bond Darlings to Ticking Bombs - Bloomberg

2018-04-10 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
VTBR DSLV VIIX DGLD CSSLF VIIZ 36GK CS AMUN CSGKF UGLD ZIV USLV TVIX XIV

3
Abraaj to Consider Sale of Stake in Fund Unit to Raise Cash - Bloomberg

2018-03-26 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
IFK IFX AMUN

36
Deutsche Bank to raise up to US$2.2b in DWS unit IPO

2018-03-13 thestar.com.my
Important achievement: A successful offering of DWS after a surge in market volatility would mark an important achievement for Deutsche Bank chief executive officer John Cryan, who proposed the sale a year ago to help bolster the lender’s capital. — Bloomberg
83SF BCS.PR BCS.PRD BCS BCS.PRC DB 83SK BCS.PRA AMUN 47MC

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to EPA:AMUN / AMUNDI on message board site Silicon Investor.

Barramundi Gold